330 related articles for article (PubMed ID: 29888503)
1. Elevation of the TP53 isoform Δ133p53β in glioblastomas: an alternative to mutant p53 in promoting tumor development.
Kazantseva M; Eiholzer RA; Mehta S; Taha A; Bowie S; Roth I; Zhou J; Joruiz SM; Royds JA; Hung NA; Slatter TL; Braithwaite AW
J Pathol; 2018 Sep; 246(1):77-88. PubMed ID: 29888503
[TBL] [Abstract][Full Text] [Related]
2. Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide.
Wang X; Chen JX; Liu JP; You C; Liu YH; Mao Q
Ann Surg Oncol; 2014 Apr; 21(4):1337-44. PubMed ID: 24248532
[TBL] [Abstract][Full Text] [Related]
3.
Gadea G; Arsic N; Fernandes K; Diot A; Joruiz SM; Abdallah S; Meuray V; Vinot S; Anguille C; Remenyi J; Khoury MP; Quinlan PR; Purdie CA; Jordan LB; Fuller-Pace FV; de Toledo M; Cren M; Thompson AM; Bourdon JC; Roux P
Elife; 2016 Sep; 5():. PubMed ID: 27630122
[No Abstract] [Full Text] [Related]
4. TP53 mutated glioblastoma stem-like cell cultures are sensitive to dual mTORC1/2 inhibition while resistance in TP53 wild type cultures can be overcome by combined inhibition of mTORC1/2 and Bcl-2.
Venkatesan S; Hoogstraat M; Caljouw E; Pierson T; Spoor JK; Zeneyedpour L; Dubbink HJ; Dekker LJ; van der Kaaij M; Kloezeman J; Berghauser Pont LM; Besselink NJ; Luider TM; Joore J; Martens JW; Lamfers ML; Sleijfer S; Leenstra S
Oncotarget; 2016 Sep; 7(36):58435-58444. PubMed ID: 27533080
[TBL] [Abstract][Full Text] [Related]
5. The SIAH1-HIPK2-p53ser46 Damage Response Pathway is Involved in Temozolomide-Induced Glioblastoma Cell Death.
He Y; Roos WP; Wu Q; Hofmann TG; Kaina B
Mol Cancer Res; 2019 May; 17(5):1129-1141. PubMed ID: 30796178
[TBL] [Abstract][Full Text] [Related]
6. Phospholipase D1 inhibition sensitizes glioblastoma to temozolomide and suppresses its tumorigenicity.
Kang DW; Hwang WC; Noh YN; Park KS; Min DS
J Pathol; 2020 Nov; 252(3):304-316. PubMed ID: 32725633
[TBL] [Abstract][Full Text] [Related]
7. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
[TBL] [Abstract][Full Text] [Related]
8. TP53 gain-of-function mutation promotes inflammation in glioblastoma.
Ham SW; Jeon HY; Jin X; Kim EJ; Kim JK; Shin YJ; Lee Y; Kim SH; Lee SY; Seo S; Park MG; Kim HM; Nam DH; Kim H
Cell Death Differ; 2019 Mar; 26(3):409-425. PubMed ID: 29786075
[TBL] [Abstract][Full Text] [Related]
9. The p53 isoform, Δ133p53α, stimulates angiogenesis and tumour progression.
Bernard H; Garmy-Susini B; Ainaoui N; Van Den Berghe L; Peurichard A; Javerzat S; Bikfalvi A; Lane DP; Bourdon JC; Prats AC
Oncogene; 2013 Apr; 32(17):2150-60. PubMed ID: 22733133
[TBL] [Abstract][Full Text] [Related]
10. Tumor associated CD70 expression is involved in promoting tumor migration and macrophage infiltration in GBM.
Ge H; Mu L; Jin L; Yang C; Chang YE; Long Y; DeLeon G; Deleyrolle L; Mitchell DA; Kubilis PS; Lu D; Qi J; Gu Y; Lin Z; Huang J
Int J Cancer; 2017 Oct; 141(7):1434-1444. PubMed ID: 28612394
[TBL] [Abstract][Full Text] [Related]
11. ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma.
Tong L; Li J; Li Q; Wang X; Medikonda R; Zhao T; Li T; Ma H; Yi L; Liu P; Xie Y; Choi J; Yu S; Lin Y; Dong J; Huang Q; Jin X; Lim M; Yang X
Theranostics; 2020; 10(13):5943-5956. PubMed ID: 32483429
[TBL] [Abstract][Full Text] [Related]
12. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC
Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000
[TBL] [Abstract][Full Text] [Related]
13. The p53 isoform Δ133p53β promotes cancer stem cell potential.
Arsic N; Gadea G; Lagerqvist EL; Busson M; Cahuzac N; Brock C; Hollande F; Gire V; Pannequin J; Roux P
Stem Cell Reports; 2015 Apr; 4(4):531-40. PubMed ID: 25754205
[TBL] [Abstract][Full Text] [Related]
14. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma.
Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y
Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952
[TBL] [Abstract][Full Text] [Related]
15. Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?
He Y; Kaina B
Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30925722
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide.
Forte IM; Indovina P; Iannuzzi CA; Cirillo D; Di Marzo D; Barone D; Capone F; Pentimalli F; Giordano A
Int J Oncol; 2019 Jun; 54(6):2189-2199. PubMed ID: 31081046
[TBL] [Abstract][Full Text] [Related]
17. Increased Expression of the Δ133p53β Isoform Enhances Brain Metastasis.
Jesus ANB; Taha A; Wang D; Mehta PM; Mehta S; Reily-Bell A; Lekamlage SP; Saraiva AM; Tahmeedzaman T; Ziad F; Thotathil Z; Gan PYC; Royds J; Braithwaite A; Hung N; Slatter TL
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674782
[TBL] [Abstract][Full Text] [Related]
18. A reappraisal of macrophage polarization in glioblastoma: Histopathological and immunohistochemical findings and review of the literature.
Mignogna C; Signorelli F; Vismara MF; Zeppa P; Camastra C; Barni T; Donato G; Di Vito A
Pathol Res Pract; 2016 Jun; 212(6):491-9. PubMed ID: 27101800
[TBL] [Abstract][Full Text] [Related]
19. TP53 disruptive mutation predicts platinum-based chemotherapy and PD-1/PD-L1 blockade response in urothelial carcinoma.
Jin K; Xu J; Su X; Xu Z; Li B; Liu G; Liu H; Wang Y; Zhu Y; Xu L; Zhang W; Liu Z; Wang Z; Chang Y; Xu J
J Pathol; 2024 Jun; 263(2):139-149. PubMed ID: 38380548
[TBL] [Abstract][Full Text] [Related]
20. Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab.
Tamura R; Tanaka T; Ohara K; Miyake K; Morimoto Y; Yamamoto Y; Kanai R; Akasaki Y; Murayama Y; Tamiya T; Yoshida K; Sasaki H
Cancer Sci; 2019 Feb; 110(2):499-508. PubMed ID: 30467920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
